RNS Number : 8862C
Haleon PLC
05 May 2026
Haleon plc: Aggregated information - transactions in own shares
5 May 2026: Haleon plc (the "Company" or "Haleon") today announces the purchase of 12,171,987 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under its share buyback programme announced on 12 March 2026.
London Stock Exchange
CBOE (UK)/BXE
CBOE (UK)/CXE
Aquis
Date of purchase:
27 April 2026
Number of Shares purchased:
1,308,429
656,619
797,997
-
Highest price paid per Share (p):
353.3000
353.3000
353.3000
-
Lowest price paid per Share (p):
349.4000
349.4000
349.4000
-
Volume weighted average price paid per Share (p):
350.8780
350.7867
350.8309
-
Date of purchase:
28 April 2026
Number of Shares purchased:
556,329
371,197
472,474
-
Highest price paid per Share (p):
351.8000
351.8000
351.8000
-
Lowest price paid per Share (p):
348.5000
348.4000
348.5000
-
Volume weighted average price paid per Share (p):
349.9766
349.9554
349.9275
-
Date of purchase:
29 April 2026
Number of Shares purchased:
2,359,494
1,639,812
898,835
347,887
Highest price paid per Share (p):
359.6000
359.6000
360.0000
345.3000
Lowest price paid per Share (p):
333.8000
333.8000
334.5000
336.5000
Volume weighted average price paid per Share (p):
338.4335
338.3904
339.5767
340.2554
Date of purchase:
30 April 2026
Number of Shares purchased:
524,892
381,406
391,616
-
Highest price paid per Share (p):
342.9000
342.9000
342.8000
-
Lowest price paid per Share (p):
338.7000
338.7000
338.7000
-
Volume weighted average price paid per Share (p):
340.6250
340.6757
340.6498
-
Date of purchase:
1 May 2026
Number of Shares purchased:
639,274
249,799
575,927
-
Highest price paid per Share (p):
343.8000
343.1000
343.8000
-
Lowest price paid per Share (p):
336.0000
336.0000
336.0000
-
Volume weighted average price paid per Share (p):
339.4396
339.5013
339.4039
-
Following the settlement of the above, the Company's registered share capital is 8,890,467,595 ordinary shares of £0.01 each, of which 12,240,797 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,878,226,798 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:
http://www.rns-pdf.londonstockexchange.com/rns/8862C_1-2026-5-1.pdf
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.
Enquiries
Investors
Media
Jo Russell
+44 7787 392441
ZoëBird
+44 7736 746167
Rakesh Patel
+44 7552 484646
Victoria Durman
+44 7894 505730
Email:investor-relations@haleon.com
Email:corporate.media@haleon.com
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.
For more information, please visit www.haleon.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
POSBLGDUBUGDGLB
